ssRNA Viruses positive-sense

CCHEMISTRY METALLURGY C12Biochemistry C12NMICRO-ORGANISMS OR ENZYMES COMPOSITIONS THEREOF PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS MUTATION OR GENETIC ENGINEERING CULTURE MEDIA

C12N2770/00ssRNA Viruses positive-sense

C12N2770/00011ssRNA Viruses positive-sense C12N2770/00021Viruses as such C12N2770/00022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/00023Virus like particles [VLP] C12N2770/00031Uses of virus other than therapeutic or vaccine C12N2770/00032Use of virus as therapeutic agent, other than vaccine C12N2770/00033Use of viral protein as therapeutic agent other than vaccine C12N2770/00034Use of virus or viral component as vaccine C12N2770/00041Use of virus, viral particle or viral elements as a vector C12N2770/00042virus or viral particle as vehicle C12N2770/00043viral genome or elements thereof as genetic vector C12N2770/00044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/00045Special targeting system for viral vectors C12N2770/00051Methods of production or purification of viral material C12N2770/00052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/00061Methods of inactivation or attenuation C12N2770/00062by genetic engineering C12N2770/00063by chemical treatment C12N2770/00064by serial passage C12N2770/00071Demonstrated in vivo effect C12N2770/00088For redistribution C12N2770/10011Arteriviridae C12N2770/10021Viruses as such C12N2770/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/10023Virus like particles [VLP] C12N2770/10031Uses of virus other than therapeutic or vaccine C12N2770/10032Use of virus as therapeutic agent, other than vaccine C12N2770/10033Use of viral protein as therapeutic agent other than vaccine C12N2770/10034Use of virus or viral component as vaccine C12N2770/10041Use of virus, viral particle or viral elements as a vector C12N2770/10042virus or viral particle as vehicle C12N2770/10043viral genome or elements thereof as genetic vector C12N2770/10044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/10045Special targeting system for viral vectors C12N2770/10051Methods of production or purification of viral material C12N2770/10052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/10061Methods of inactivation or attenuation C12N2770/10062by genetic engineering C12N2770/10063by chemical treatment C12N2770/10064by serial passage C12N2770/10071Demonstrated in vivo effect C12N2770/10088For redistribution C12N2770/12011Astroviridae C12N2770/12021Viruses as such C12N2770/12022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/12023Virus like particles [VLP] C12N2770/12031Uses of virus other than therapeutic or vaccine C12N2770/12032Use of virus as therapeutic agent, other than vaccine C12N2770/12033Use of viral protein as therapeutic agent other than vaccine C12N2770/12034Use of virus or viral component as vaccine C12N2770/12041Use of virus, viral particle or viral elements as a vector C12N2770/12042virus or viral particle as vehicle C12N2770/12043viral genome or elements thereof as genetic vector C12N2770/12044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/12045Special targeting system for viral vectors C12N2770/12051Methods of production or purification of viral material C12N2770/12052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/12061Methods of inactivation or attenuation C12N2770/12062by genetic engineering C12N2770/12063by chemical treatment C12N2770/12064by serial passage C12N2770/12071Demonstrated in vivo effect C12N2770/12088For redistribution C12N2770/14011Bromoviridae C12N2770/14021Viruses as such C12N2770/14022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/14023Virus like particles [VLP] C12N2770/14031Uses of virus other than therapeutic or vaccine C12N2770/14032Use of virus as therapeutic agent, other than vaccine C12N2770/14033Use of viral protein as therapeutic agent other than vaccine C12N2770/14034Use of virus or viral component as vaccine C12N2770/14041Use of virus, viral particle or viral elements as a vector C12N2770/14042virus or viral particle as vehicle C12N2770/14043viral genome or elements thereof as genetic vector C12N2770/14044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/14045Special targeting system for viral vectors C12N2770/14051Methods of production or purification of viral material C12N2770/14052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/14061Methods of inactivation or attenuation C12N2770/14062by genetic engineering C12N2770/14063by chemical treatment C12N2770/14064by serial passage C12N2770/14071Demonstrated in vivo effect C12N2770/14088For redistribution C12N2770/16011Caliciviridae C12N2770/16021Viruses as such C12N2770/16022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/16023Virus like particles [VLP] C12N2770/16031Uses of virus other than therapeutic or vaccine C12N2770/16032Use of virus as therapeutic agent, other than vaccine C12N2770/16033Use of viral protein as therapeutic agent other than vaccine C12N2770/16034Use of virus or viral component as vaccine C12N2770/16041Use of virus, viral particle or viral elements as a vector C12N2770/16042virus or viral particle as vehicle C12N2770/16043viral genome or elements thereof as genetic vector C12N2770/16044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/16045Special targeting system for viral vectors C12N2770/16051Methods of production or purification of viral material C12N2770/16052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/16061Methods of inactivation or attenuation C12N2770/16062by genetic engineering C12N2770/16063by chemical treatment C12N2770/16064by serial passage C12N2770/16071Demonstrated in vivo effect C12N2770/16088For redistribution C12N2770/18011Comoviridae C12N2770/18021Viruses as such C12N2770/18022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/18023Virus like particles [VLP] C12N2770/18031Uses of virus other than therapeutic or vaccine C12N2770/18032Use of virus as therapeutic agent, other than vaccine C12N2770/18033Use of viral protein as therapeutic agent other than vaccine C12N2770/18034Use of virus or viral component as vaccine C12N2770/18041Use of virus, viral particle or viral elements as a vector C12N2770/18042virus or viral particle as vehicle C12N2770/18043viral genome or elements thereof as genetic vector C12N2770/18044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/18045Special targeting system for viral vectors C12N2770/18051Methods of production or purification of viral material C12N2770/18052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/18061Methods of inactivation or attenuation C12N2770/18062by genetic engineering C12N2770/18063by chemical treatment C12N2770/18064by serial passage C12N2770/18071Demonstrated in vivo effect C12N2770/18088For redistribution C12N2770/20011Coronaviridae C12N2770/20021Viruses as such C12N2770/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/20023Virus like particles [VLP] C12N2770/20031Uses of virus other than therapeutic or vaccine C12N2770/20032Use of virus as therapeutic agent, other than vaccine C12N2770/20033Use of viral protein as therapeutic agent other than vaccine C12N2770/20034Use of virus or viral component as vaccine C12N2770/20041Use of virus, viral particle or viral elements as a vector C12N2770/20042virus or viral particle as vehicle C12N2770/20043viral genome or elements thereof as genetic vector C12N2770/20044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/20045Special targeting system for viral vectors C12N2770/20051Methods of production or purification of viral material C12N2770/20052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/20061Methods of inactivation or attenuation C12N2770/20062by genetic engineering C12N2770/20063by chemical treatment C12N2770/20064by serial passage C12N2770/20071Demonstrated in vivo effect C12N2770/20088For redistribution C12N2770/22011Dicistroviridae C12N2770/22021Viruses as such C12N2770/22022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/22023Virus like particles [VLP] C12N2770/22031Uses of virus other than therapeutic or vaccine C12N2770/22032Use of virus as therapeutic agent, other than vaccine C12N2770/22033Use of viral protein as therapeutic agent other than vaccine C12N2770/22034Use of virus or viral component as vaccine C12N2770/22041Use of virus, viral particle or viral elements as a vector C12N2770/22042virus or viral particle as vehicle C12N2770/22043viral genome or elements thereof as genetic vector C12N2770/22044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/22045Special targeting system for viral vectors C12N2770/22051Methods of production or purification of viral material C12N2770/22052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/22061Methods of inactivation or attenuation C12N2770/22062by genetic engineering C12N2770/22063by chemical treatment C12N2770/22064by serial passage C12N2770/22071Demonstrated in vivo effect C12N2770/22088For redistribution C12N2770/24011Flaviviridae C12N2770/24021Viruses as such C12N2770/24022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/24023Virus like particles [VLP] C12N2770/24031Uses of virus other than therapeutic or vaccine C12N2770/24032Use of virus as therapeutic agent, other than vaccine C12N2770/24033Use of viral protein as therapeutic agent other than vaccine C12N2770/24034Use of virus or viral component as vaccine C12N2770/24041Use of virus, viral particle or viral elements as a vector C12N2770/24042virus or viral particle as vehicle C12N2770/24043viral genome or elements thereof as genetic vector C12N2770/24044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/24045Special targeting system for viral vectors C12N2770/24051Methods of production or purification of viral material C12N2770/24052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/24061Methods of inactivation or attenuation C12N2770/24062by genetic engineering C12N2770/24063by chemical treatment C12N2770/24064by serial passage C12N2770/24071Demonstrated in vivo effect C12N2770/24088For redistribution C12N2770/24111Flavivirus C12N2770/24121Viruses as such C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/24123Virus like particles [VLP] C12N2770/24131Uses of virus other than therapeutic or vaccine C12N2770/24132Use of virus as therapeutic agent, other than vaccine C12N2770/24133Use of viral protein as therapeutic agent other than vaccine C12N2770/24134Use of virus or viral component as vaccine C12N2770/24141Use of virus, viral particle or viral elements as a vector C12N2770/24142virus or viral particle as vehicle C12N2770/24143viral genome or elements thereof as genetic vector C12N2770/24144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/24145Special targeting system for viral vectors C12N2770/24151Methods of production or purification of viral material C12N2770/24152relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/24161Methods of inactivation or attenuation C12N2770/24162by genetic engineering C12N2770/24163by chemical treatment C12N2770/24164by serial passage C12N2770/24171Demonstrated in vivo effect C12N2770/24188For redistribution C12N2770/24211Hepacivirus C12N2770/24221Viruses as such C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/24223Virus like particles [VLP] C12N2770/24231Uses of virus other than therapeutic or vaccine C12N2770/24232Use of virus as therapeutic agent, other than vaccine C12N2770/24233Use of viral protein as therapeutic agent other than vaccine C12N2770/24234Use of virus or viral component as vaccine C12N2770/24241Use of virus, viral particle or viral elements as a vector C12N2770/24242virus or viral particle as vehicle C12N2770/24243viral genome or elements thereof as genetic vector C12N2770/24244Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/24245Special targeting system for viral vectors C12N2770/24251Methods of production or purification of viral material C12N2770/24252relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/24261Methods of inactivation or attenuation C12N2770/24262by genetic engineering C12N2770/24263by chemical treatment C12N2770/24264by serial passage C12N2770/24271Demonstrated in vivo effect C12N2770/24288For redistribution C12N2770/24311Pestivirus C12N2770/24321Viruses as such C12N2770/24322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/24323Virus like particles [VLP] C12N2770/24331Uses of virus other than therapeutic or vaccine C12N2770/24332Use of virus as therapeutic agent, other than vaccine C12N2770/24333Use of viral protein as therapeutic agent other than vaccine C12N2770/24334Use of virus or viral component as vaccine C12N2770/24341Use of virus, viral particle or viral elements as a vector C12N2770/24342virus or viral particle as vehicle C12N2770/24343viral genome or elements thereof as genetic vector C12N2770/24344Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/24345Special targeting system for viral vectors C12N2770/24351Methods of production or purification of viral material C12N2770/24352relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/24361Methods of inactivation or attenuation C12N2770/24362by genetic engineering C12N2770/24363by chemical treatment C12N2770/24364by serial passage C12N2770/24371Demonstrated in vivo effect C12N2770/24388For redistribution C12N2770/26011Flexiviridae C12N2770/26021Viruses as such C12N2770/26022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/26023Virus like particles [VLP] C12N2770/26031Uses of virus other than therapeutic or vaccine C12N2770/26032Use of virus as therapeutic agent, other than vaccine C12N2770/26033Use of viral protein as therapeutic agent other than vaccine C12N2770/26034Use of virus or viral component as vaccine C12N2770/26041Use of virus, viral particle or viral elements as a vector C12N2770/26042virus or viral particle as vehicle C12N2770/26043viral genome or elements thereof as genetic vector C12N2770/26044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/26045Special targeting system for viral vectors C12N2770/26051Methods of production or purification of viral material C12N2770/26052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/26061Methods of inactivation or attenuation C12N2770/26062by genetic engineering C12N2770/26063by chemical treatment C12N2770/26064by serial passage C12N2770/26071Demonstrated in vivo effect C12N2770/26088For redistribution C12N2770/28011Hepeviridae C12N2770/28021Viruses as such C12N2770/28022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/28023Virus like particles [VLP] C12N2770/28031Uses of virus other than therapeutic or vaccine C12N2770/28032Use of virus as therapeutic agent, other than vaccine C12N2770/28033Use of viral protein as therapeutic agent other than vaccine C12N2770/28034Use of virus or viral component as vaccine C12N2770/28041Use of virus, viral particle or viral elements as a vector C12N2770/28042virus or viral particle as vehicle C12N2770/28043viral genome or elements thereof as genetic vector C12N2770/28044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/28045Special targeting system for viral vectors C12N2770/28051Methods of production or purification of viral material C12N2770/28052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/28061Methods of inactivation or attenuation C12N2770/28062by genetic engineering C12N2770/28063by chemical treatment C12N2770/28064by serial passage C12N2770/28071Demonstrated in vivo effect C12N2770/28088For redistribution C12N2770/28111Hepevirus C12N2770/28121Viruses as such C12N2770/28122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/28123Virus like particles [VLP] C12N2770/28131Uses of virus other than therapeutic or vaccine C12N2770/28132Use of virus as therapeutic agent, other than vaccine C12N2770/28133Use of viral protein as therapeutic agent other than vaccine C12N2770/28134Use of virus or viral component as vaccine C12N2770/28141Use of virus, viral particle or viral elements as a vector C12N2770/28142virus or viral particle as vehicle C12N2770/28143viral genome or elements thereof as genetic vector C12N2770/28144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/28145Special targeting system for viral vectors C12N2770/28151Methods of production or purification of viral material C12N2770/28152relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/28161Methods of inactivation or attenuation C12N2770/28162by genetic engineering C12N2770/28163by chemical treatment C12N2770/28164by serial passage C12N2770/28171Demonstrated in vivo effect C12N2770/28188For redistribution C12N2770/30011Nodaviridae C12N2770/30021Viruses as such C12N2770/30022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/30023Virus like particles [VLP] C12N2770/30031Uses of virus other than therapeutic or vaccine C12N2770/30032Use of virus as therapeutic agent, other than vaccine C12N2770/30033Use of viral protein as therapeutic agent other than vaccine C12N2770/30034Use of virus or viral component as vaccine C12N2770/30041Use of virus, viral particle or viral elements as a vector C12N2770/30042virus or viral particle as vehicle C12N2770/30043viral genome or elements thereof as genetic vector C12N2770/30044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/30045Special targeting system for viral vectors C12N2770/30051Methods of production or purification of viral material C12N2770/30052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/30061Methods of inactivation or attenuation C12N2770/30062by genetic engineering C12N2770/30063by chemical treatment C12N2770/30064by serial passage C12N2770/30071Demonstrated in vivo effect C12N2770/30088For redistribution C12N2770/32011Picornaviridae C12N2770/32021Viruses as such C12N2770/32022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/32023Virus like particles [VLP] C12N2770/32031Uses of virus other than therapeutic or vaccine C12N2770/32032Use of virus as therapeutic agent, other than vaccine C12N2770/32033Use of viral protein as therapeutic agent other than vaccine C12N2770/32034Use of virus or viral component as vaccine C12N2770/32041Use of virus, viral particle or viral elements as a vector C12N2770/32042virus or viral particle as vehicle C12N2770/32043viral genome or elements thereof as genetic vector C12N2770/32044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/32045Special targeting system for viral vectors C12N2770/32051Methods of production or purification of viral material C12N2770/32052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/32061Methods of inactivation or attenuation C12N2770/32062by genetic engineering C12N2770/32063by chemical treatment C12N2770/32064by serial passage C12N2770/32071Demonstrated in vivo effect C12N2770/32088For redistribution C12N2770/32111Aphthovirus C12N2770/32121Viruses as such C12N2770/32122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/32123Virus like particles [VLP] C12N2770/32131Uses of virus other than therapeutic or vaccine C12N2770/32132Use of virus as therapeutic agent, other than vaccine C12N2770/32133Use of viral protein as therapeutic agent other than vaccine C12N2770/32134Use of virus or viral component as vaccine C12N2770/32141Use of virus, viral particle or viral elements as a vector C12N2770/32142virus or viral particle as vehicle C12N2770/32143viral genome or elements thereof as genetic vector C12N2770/32144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/32145Special targeting system for viral vectors C12N2770/32151Methods of production or purification of viral material C12N2770/32152relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/32161Methods of inactivation or attenuation C12N2770/32162by genetic engineering C12N2770/32163by chemical treatment C12N2770/32164by serial passage C12N2770/32171Demonstrated in vivo effect C12N2770/32188For redistribution C12N2770/32211Cardiovirus C12N2770/32221Viruses as such C12N2770/32222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/32223Virus like particles [VLP] C12N2770/32231Uses of virus other than therapeutic or vaccine C12N2770/32232Use of virus as therapeutic agent, other than vaccine C12N2770/32233Use of viral protein as therapeutic agent other than vaccine C12N2770/32234Use of virus or viral component as vaccine C12N2770/32241Use of virus, viral particle or viral elements as a vector C12N2770/32242virus or viral particle as vehicle C12N2770/32243viral genome or elements thereof as genetic vector C12N2770/32244Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/32245Special targeting system for viral vectors C12N2770/32251Methods of production or purification of viral material C12N2770/32252relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/32261Methods of inactivation or attenuation C12N2770/32262by genetic engineering C12N2770/32263by chemical treatment C12N2770/32264by serial passage C12N2770/32271Demonstrated in vivo effect C12N2770/32288For redistribution C12N2770/32311Enterovirus C12N2770/32321Viruses as such C12N2770/32322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/32323Virus like particles [VLP] C12N2770/32331Uses of virus other than therapeutic or vaccine C12N2770/32332Use of virus as therapeutic agent, other than vaccine C12N2770/32333Use of viral protein as therapeutic agent other than vaccine C12N2770/32334Use of virus or viral component as vaccine C12N2770/32341Use of virus, viral particle or viral elements as a vector C12N2770/32342virus or viral particle as vehicle C12N2770/32343viral genome or elements thereof as genetic vector C12N2770/32344Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/32345Special targeting system for viral vectors C12N2770/32351Methods of production or purification of viral material C12N2770/32352relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/32361Methods of inactivation or attenuation C12N2770/32362by genetic engineering C12N2770/32363by chemical treatment C12N2770/32364by serial passage C12N2770/32371Demonstrated in vivo effect C12N2770/32388For redistribution C12N2770/32411Hepatovirus C12N2770/32421Viruses as such C12N2770/32422New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/32423Virus like particles [VLP] C12N2770/32431Uses of virus other than therapeutic or vaccine C12N2770/32432Use of virus as therapeutic agent, other than vaccine C12N2770/32433Use of viral protein as therapeutic agent other than vaccine C12N2770/32434Use of virus or viral component as vaccine C12N2770/32441Use of virus, viral particle or viral elements as a vector C12N2770/32442virus or viral particle as vehicle C12N2770/32443viral genome or elements thereof as genetic vector C12N2770/32444Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/32445Special targeting system for viral vectors C12N2770/32451Methods of production or purification of viral material C12N2770/32452relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/32461Methods of inactivation or attenuation C12N2770/32462by genetic engineering C12N2770/32463by chemical treatment C12N2770/32464by serial passage C12N2770/32471Demonstrated in vivo effect C12N2770/32488For redistribution C12N2770/32511Parechovirus C12N2770/32521Viruses as such C12N2770/32522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/32523Virus like particles [VLP] C12N2770/32531Uses of virus other than therapeutic or vaccine C12N2770/32532Use of virus as therapeutic agent, other than vaccine C12N2770/32533Use of viral protein as therapeutic agent other than vaccine C12N2770/32534Use of virus or viral component as vaccine C12N2770/32541Use of virus, viral particle or viral elements as a vector C12N2770/32542virus or viral particle as vehicle C12N2770/32543viral genome or elements thereof as genetic vector C12N2770/32544Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/32545Special targeting system for viral vectors C12N2770/32551Methods of production or purification of viral material C12N2770/32552relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/32561Methods of inactivation or attenuation C12N2770/32562by genetic engineering C12N2770/32563by chemical treatment C12N2770/32564by serial passage C12N2770/32571Demonstrated in vivo effect C12N2770/32588For redistribution C12N2770/32611Poliovirus C12N2770/32621Viruses as such C12N2770/32622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/32623Virus like particles [VLP] C12N2770/32631Uses of virus other than therapeutic or vaccine C12N2770/32632Use of virus as therapeutic agent, other than vaccine C12N2770/32633Use of viral protein as therapeutic agent other than vaccine C12N2770/32634Use of virus or viral component as vaccine C12N2770/32641Use of virus, viral particle or viral elements as a vector C12N2770/32642virus or viral particle as vehicle C12N2770/32643viral genome or elements thereof as genetic vector C12N2770/32644Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/32645Special targeting system for viral vectors C12N2770/32651Methods of production or purification of viral material C12N2770/32652relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/32661Methods of inactivation or attenuation C12N2770/32662by genetic engineering C12N2770/32663by chemical treatment C12N2770/32664by serial passage C12N2770/32671Demonstrated in vivo effect C12N2770/32688For redistribution C12N2770/32711Rhinovirus C12N2770/32721Viruses as such C12N2770/32722New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/32723Virus like particles [VLP] C12N2770/32731Uses of virus other than therapeutic or vaccine C12N2770/32732Use of virus as therapeutic agent, other than vaccine C12N2770/32733Use of viral protein as therapeutic agent other than vaccine C12N2770/32734Use of virus or viral component as vaccine C12N2770/32741Use of virus, viral particle or viral elements as a vector C12N2770/32742virus or viral particle as vehicle C12N2770/32743viral genome or elements thereof as genetic vector C12N2770/32744Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/32745Special targeting system for viral vectors C12N2770/32751Methods of production or purification of viral material C12N2770/32752relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/32761Methods of inactivation or attenuation C12N2770/32762by genetic engineering C12N2770/32763by chemical treatment C12N2770/32764by serial passage C12N2770/32771Demonstrated in vivo effect C12N2770/32788For redistribution C12N2770/34011Potyviridae C12N2770/34021Viruses as such C12N2770/34022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/34023Virus like particles [VLP] C12N2770/34031Uses of virus other than therapeutic or vaccine C12N2770/34032Use of virus as therapeutic agent, other than vaccine C12N2770/34033Use of viral protein as therapeutic agent other than vaccine C12N2770/34034Use of virus or viral component as vaccine C12N2770/34041Use of virus, viral particle or viral elements as a vector C12N2770/34042virus or viral particle as vehicle C12N2770/34043viral genome or elements thereof as genetic vector C12N2770/34044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/34045Special targeting system for viral vectors C12N2770/34051Methods of production or purification of viral material C12N2770/34052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/34061Methods of inactivation or attenuation C12N2770/34062by genetic engineering C12N2770/34063by chemical treatment C12N2770/34064by serial passage C12N2770/34071Demonstrated in vivo effect C12N2770/34088For redistribution C12N2770/36011Togaviridae C12N2770/36021Viruses as such C12N2770/36022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/36023Virus like particles [VLP] C12N2770/36031Uses of virus other than therapeutic or vaccine C12N2770/36032Use of virus as therapeutic agent, other than vaccine C12N2770/36033Use of viral protein as therapeutic agent other than vaccine C12N2770/36034Use of virus or viral component as vaccine C12N2770/36041Use of virus, viral particle or viral elements as a vector C12N2770/36042virus or viral particle as vehicle C12N2770/36043viral genome or elements thereof as genetic vector C12N2770/36044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/36045Special targeting system for viral vectors C12N2770/36051Methods of production or purification of viral material C12N2770/36052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/36061Methods of inactivation or attenuation C12N2770/36062by genetic engineering C12N2770/36063by chemical treatment C12N2770/36064by serial passage C12N2770/36071Demonstrated in vivo effect C12N2770/36088For redistribution C12N2770/36111Alphavirus C12N2770/36121Viruses as such C12N2770/36122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/36123Virus like particles [VLP] C12N2770/36131Uses of virus other than therapeutic or vaccine C12N2770/36132Use of virus as therapeutic agent, other than vaccine C12N2770/36133Use of viral protein as therapeutic agent other than vaccine C12N2770/36134Use of virus or viral component as vaccine C12N2770/36141Use of virus, viral particle or viral elements as a vector C12N2770/36142virus or viral particle as vehicle C12N2770/36143viral genome or elements thereof as genetic vector C12N2770/36144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/36145Special targeting system for viral vectors C12N2770/36151Methods of production or purification of viral material C12N2770/36152relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/36161Methods of inactivation or attenuation C12N2770/36162by genetic engineering C12N2770/36163by chemical treatment C12N2770/36164by serial passage C12N2770/36171Demonstrated in vivo effect C12N2770/36188For redistribution C12N2770/36211Rubivirus C12N2770/36221Viruses as such C12N2770/36222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/36223Virus like particles [VLP] C12N2770/36231Uses of virus other than therapeutic or vaccine C12N2770/36232Use of virus as therapeutic agent, other than vaccine C12N2770/36233Use of viral protein as therapeutic agent other than vaccine C12N2770/36234Use of virus or viral component as vaccine C12N2770/36241Use of virus, viral particle or viral elements as a vector C12N2770/36242virus or viral particle as vehicle C12N2770/36243viral genome or elements thereof as genetic vector C12N2770/36244Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/36245Special targeting system for viral vectors C12N2770/36251Methods of production or purification of viral material C12N2770/36252relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/36261Methods of inactivation or attenuation C12N2770/36262by genetic engineering C12N2770/36263by chemical treatment C12N2770/36264by serial passage C12N2770/36271Demonstrated in vivo effect C12N2770/36288For redistribution C12N2770/38011Tombusviridae C12N2770/38021Viruses as such C12N2770/38022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/38023Virus like particles [VLP] C12N2770/38031Uses of virus other than therapeutic or vaccine C12N2770/38032Use of virus as therapeutic agent, other than vaccine C12N2770/38033Use of viral protein as therapeutic agent other than vaccine C12N2770/38034Use of virus or viral component as vaccine C12N2770/38041Use of virus, viral particle or viral elements as a vector C12N2770/38042virus or viral particle as vehicle C12N2770/38043viral genome or elements thereof as genetic vector C12N2770/38044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/38045Special targeting system for viral vectors C12N2770/38051Methods of production or purification of viral material C12N2770/38052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/38061Methods of inactivation or attenuation C12N2770/38062by genetic engineering C12N2770/38063by chemical treatment C12N2770/38064by serial passage C12N2770/38071Demonstrated in vivo effect C12N2770/38088For redistribution C12N2770/40011Tymoviridae C12N2770/40021Viruses as such C12N2770/40022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2770/40023Virus like particles [VLP] C12N2770/40031Uses of virus other than therapeutic or vaccine C12N2770/40032Use of virus as therapeutic agent, other than vaccine C12N2770/40033Use of viral protein as therapeutic agent other than vaccine C12N2770/40034Use of virus or viral component as vaccine C12N2770/40041Use of virus, viral particle or viral elements as a vector C12N2770/40042virus or viral particle as vehicle C12N2770/40043viral genome or elements thereof as genetic vector C12N2770/40044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2770/40045Special targeting system for viral vectors C12N2770/40051Methods of production or purification of viral material C12N2770/40052relating to complementing cells and packaging systems for producing virus or viral particles C12N2770/40061Methods of inactivation or attenuation C12N2770/40062by genetic engineering C12N2770/40063by chemical treatment C12N2770/40064by serial passage C12N2770/40071Demonstrated in vivo effect C12N2770/40088For redistribution